PGK1 Suppresses CD8 + T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma
Advanced Science · 2026
DOI: 10.1002/advs.75801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xi Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangz…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Phosphoglycerate Kinase, Chemokine CCL2, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Project of Jinan Microecological Biomedicine Shandong Laboratory, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis and few effective treatments. The highly immunosuppressive tumor microenvironment and multifaceted immune escape mechanisms in HCC profoundly restrict the clinical efficacy of immune checkpoint inhibitors. Phosphoglycerate kinase 1 (PGK1) is established as an oncogenic driver in malignant tumor progression. However, its role in modulating tumor immunity remains elusive. This study found that HCC cell‐intrinsic PGK1 contributed to tumor progression through inhibiting CD8 + T cell‐mediated antitumor immunity. Then, in vivo and in vitro results demonstrated that tumor‐associated macrophages (TAMs) function as critical mediators in PGK1‐driven immunosuppression. Furthermore, PGK1 promoted the recruitment and M2 polarization of TAMs through upregulation of C‐C motif chemokine ligand 2 (CCL2) expression. Blockade of CCL2 significantly attenuated PGK1‐induced infiltration of C‐C motif chemokine receptor 2 (CCR2) + TAMs and inhibited M2 polarization, while reversing the impaired infiltration and function of CD8 + T cells. This work further demonstrated that PGK1 enhanced CCL2 secretion through activating the AKT/GSK3β/β‐catenin pathway in HCC cells. In vivo experiments revealed that the combination of PGK1 inhibitor and immunotherapy elicited potent antitumor efficacy. Taken together, this study highlighted PGK1 as a pivotal regulator of tumor immunobiology and provided novel insights into combination immunotherapy for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- NHC Key Laboratory of Combined Multi-Organ Transplantation, Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China.
- Institute of Organ Transplantation, Zhejiang University, Hangzhou, China.
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Hangzhou, China.
- Department of Hepaticobiliarypancreatic and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Yiting Qiao, Haiyang Xie, Shusen Zheng
Förderung
- National Natural Science Foundation of China
- Research Project of Jinan Microecological Biomedicine Shandong Laboratory
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- Key R&D Program of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Key Research and Development Project of Zhejiang Province
- Hainan Province Science and Technology Special Fund
Zitieren
APA
Liu, X., Liu, J., Zhang, Z., Yu, X., Qian, J., Ding, L., Wu, Q., Yang, Z., Luo, X. Y., Ding, X., Su, R., Yu, X., Qiao, Y., Yin, S., Xie, H., Zhou, L., Liu, Y., & Zheng, S. (2026). PGK1 Suppresses CD8 + T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma. Advanced Science. https://doi.org/10.1002/advs.75801
Vancouver
Liu X, Liu J, Zhang Z, Yu X, Qian J, Ding L, et al. PGK1 Suppresses CD8 + T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma. Advanced Science. 2026. doi:10.1002/advs.75801
BibTeX
@article{Liu2026,
author = {Liu, Xi and Liu, Jianpeng and Zhang, Zhihao and Yu, Xizhi and Qian, Junjie and Ding, Limin and Wu, Qinchuan and Yang, Zhe and Luo, Xing-Yu and Ding, Xinjiang and Su, Rong and Yu, Xiaobo and Qiao, Yiting and Yin, Shengyong and Xie, Haiyang and Zhou, Lin and Liu, Yuanxing and Zheng, Shusen},
title = {PGK1 Suppresses CD8 + T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.75801}
}
EUVIMED